Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Virogin Biotech Canada Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05266612
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸MD Anderson, Houston, Texas, United States
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Intrahepatic CholangiocarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Virogin Biotech Canada Ltd
- Target Recruit Count
- 97
- Registration Number
- NCT05223816
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath